UNSPSC 51293010: Amineptine hydrochloride

This classification denotes an antidepressant agent with the molecular formula C22H27NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A5P604A12R, chemically known as 7-((10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-yl)amino)heptanoic acid hydrochloride but more generally known as amineptine hydrochloride, which bears US NIH Compound Identifier 34869. European Medicines Agency schedules Amineptine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00447MIG.

Most nations, for tariff and trade purposes, schedule amineptine hydrochloride under HS 29224995 and SITC 51465. As of Q4 2014, AMINEPTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)CCC3CCCCC3C2NCCCCCCC(=O)O.CL.

UNSPSC 51293010 Amineptine hydrochloride is a Commodity code representing a specific pharmaceutical compound, but recent state and local procurement activity tagged to this code does not reflect purchases of amineptine itself. Instead, the three most recent opportunities solicited under this code involve naloxone products, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals—none of which are amineptine. The mismatch suggests either tagging error in the underlying procurement records or that state and local buyers are using this code as a proxy for broader pharmaceutical procurement when the specific product is not available as a distinct line item. What state and local governments are actually buying under this code designation spans emergency-response medications (naloxone), pharmacy benefit program services (direct contracting with manufacturers), and generic pharmaceutical distribution through authorized wholesalers. Issuing bodies range from county health departments (Seminole County, Florida) to state health and human services commissions (Texas HHS) to multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota, Oregon, and other participating jurisdictions). The cooperative purchasing model dominates recent activity, with MMCAP distributing contracts across participating states and local governments rather than individual agencies procuring independently.

Geographic activity concentrates in Florida, Texas, and Minnesota through the MMCAP cooperative. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2026; the Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs, indicating exploratory procurement prior to formal RFP; and MMCAP issued RFP S1070000015802 in January 2026 for generic pharmaceuticals and OTC products across multiple state and local participants, with proposals due March 26, 2026 and contracts effective July 1, 2026. The MMCAP RFP requires vendors to work through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and mandates cGMP and Drug Supply Chain Security Act compliance, with pricing weighted at 75 percent of evaluation. No recent activity shows direct procurement of amineptine hydrochloride by name.